Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.37 |
| ▸ | MAOB | P27338 | 8/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CALML3 | P27482 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SDHA | P31040 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862213 | 0.92 | MAOA (0.46) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL5861012 | 0.89 | MAOB (0.36) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL5862218 | 0.86 | MAOA (0.39) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL5862127 | 0.81 | MAOA (0.58) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL5862835 | 0.78 | MAOA (0.48) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL5860953 | 0.75 | MAOA (0.37) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL4757260 | 0.72 | MAOB (0.47) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL4638720 | 0.71 | TSHR (0.57) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL4638728 | 0.71 | TSHR (0.57) | MAOAMAOBLMNACALML3PTGS1 | |
| SCHEMBL1224894 | 0.70 | MAOA (0.52) | MAOAMAOBLMNACALML3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599470-A1 | ANTIBACTERIAL INDOLONE OXAZOLIDINONES, INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia & Upjohn Company LLC (US) | 2005-11-30 | — | — | EP | claimed |
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY | 2004-09-09 | — | — | US | claimed |
| WO-2004074282-A1 | ANTIBACTERIAL INDOLONE OXAZOLIDINONES, INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-09-02 | — | — | WO | claimed |
| US-7012088-B2 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1599470-A1 | ANTIBACTERIAL INDOLONE OXAZOLIDINONES, INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia & Upjohn Company LLC (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004074282-A1 | ANTIBACTERIAL INDOLONE OXAZOLIDINONES, INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | OXA1L, IDO1, NDUFS7 | MAOA 635/4885MAOB 670/4885LMNA 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.